Published in PLoS Med on September 01, 2006
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
HIV-1 Nef: at the crossroads. Retrovirology (2008) 1.88
Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A (2008) 1.43
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology (2012) 1.12
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother (2012) 1.11
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci U S A (2008) 1.10
Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Biophys J (2009) 0.97
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97
Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol (2009) 0.95
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93
Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol (2013) 0.89
Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1. Antimicrob Agents Chemother (2010) 0.86
Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection. PLoS One (2013) 0.86
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother (2010) 0.85
An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharm (2015) 0.84
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. Clin Med Ther (2009) 0.83
Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture. J Acquir Immune Defic Syndr (2012) 0.81
Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS (2016) 0.80
Liposomes for HIV prophylaxis. Biomaterials (2011) 0.79
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol (2006) 3.13
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov (2002) 2.78
Adherent biofilms in bacterial vaginosis. Obstet Gynecol (2005) 2.31
Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis (2004) 2.29
Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol (2006) 2.28
Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses (2004) 2.22
In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr (2005) 1.99
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses (2003) 1.92
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Med (2005) 1.85
Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception (2000) 1.72
SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses (2005) 1.63
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis (2002) 1.54
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol (2005) 1.54
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother (2005) 1.48
'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS (2001) 1.48
Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception (2004) 1.47
Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A (2005) 1.39
Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod (2001) 1.32
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother (2006) 1.31
How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med (2006) 1.20
Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2005) 1.19
Residence half-life of IgG administered topically to the mouse vagina. Biol Reprod (1996) 1.11
Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis (2005) 1.07
Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother (2005) 1.03
Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr (2005) 1.02
Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus. AIDS (2005) 0.96
Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol Bioeng (2000) 0.83
Single-dose nevirapine and drug resistance: the more you look, the more you find. J Infect Dis (2005) 0.82
The effect of nonoxynol-9 on human endometrium. Contraception (2005) 0.80
The development of novel vaginal microbicides: from the bench to the clinic. AIDS (2001) 0.78
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Online submission makes authors do all the work. Nature (2005) 3.21
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Target cells in vaginal HIV transmission. Microbes Infect (2003) 2.36
Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses (2004) 2.22
Whither or wither microbicides? Science (2008) 2.17
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol (2006) 2.12
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A (2009) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology (2004) 1.72
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2005) 1.68
Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology (2006) 1.59
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology (2006) 1.58
Vaginal microbicides: moving ahead after an unexpected setback. AIDS (2007) 1.56
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A (2009) 1.55
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol (2013) 1.54
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A (2009) 1.53
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (2014) 1.53
HIV-1 infection of human penile explant tissue and protection by candidate microbicides. AIDS (2009) 1.49
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol (2005) 1.42
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem (2012) 1.42
Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology (2010) 1.41
Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology (2005) 1.40
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol (2013) 1.38
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine (2009) 1.37
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 1.34
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol (2003) 1.29
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog (2009) 1.29
Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol (2009) 1.28
Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother (2009) 1.26
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology (2004) 1.23
Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog (2007) 1.23
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS (2007) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology (2007) 1.21
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry (2009) 1.20
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif (2006) 1.19
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses (2010) 1.18
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood (2003) 1.18
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother (2012) 1.14
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry (2007) 1.13
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Programming desiccation-tolerance: from plants to seeds to resurrection plants. Curr Opin Plant Biol (2011) 1.12
Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology (2009) 1.11
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses (2003) 1.10